Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, goto-kakizaki rat by a GLP-1 receptor-mediated mechanism

Journal of Gastrointestinal Surgery

Volumn 13, Issue 10, 2009, Pages 1762-1772

  Kindel, Tammy L ^a   Yoder, Stephanie M ^a   Seeley, Randy J ^a   D'Alessio, David A ^a   Tso, Patrick ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Gastric bypass; Glucagon like peptide 1; Ileal interposition; Incretin

Indexed keywords

GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR;

ANIMAL; ARTICLE; BARIATRIC SURGERY; COMPARATIVE STUDY; DISEASE MODEL; DUODENUM; GLUCOSE INTOLERANCE; ILEUM; JEJUNUM; MALE; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; RAT; STOMACH BYPASS; WISTAR RAT;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DUODENUM; GASTRIC BYPASS; GLUCOSE INTOLERANCE; ILEUM; JEJUNUM; MALE; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON;

EID: 70350380343     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-0912-9     Document Type: Article

References (59)

1. Livingston EH. Procedure incidence and in-hospital complication rates of bariatric surgery in the United States. Am J Surg 2004;188:105-110. doi:10.1016/j.amjsurg.2004.03.001.
2. Parikh M, Ayoung-Chee P, Romanos E, Lewis N, Pachter HL, Fielding G, Ren C. Comparison of rates of resolution of diabetes mellitus after gastric banding, gastric bypass, and biliopancreatic diversion. J Am Coll Surg 2007;205:631-635. doi:10.1016/j.jamcollsurg.2007.05.033.
3. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, Dohm L. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-350. doi:10.1097/00000658-199509000-00011.
4. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003;238:467-484.
5. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension, and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7:477-484.
6. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693. doi:10.1056/NEJMoa035622.
7. Yan E, Ko E, Luong V, Wang HJ, Romanova M, Li Z. Long-term changes in weight loss and obesity-related comorbidities after Roux-en-Y gastric bypass: a primary care experience. Am J Surg 2008;195:94-98. doi:10.1016/j.amjsurg.2007.01.036.
8. Pories W, Albrecht R. Etiology of type II diabetes mellitus: role of the foregut. World J Surg 2001;25:527-531. doi:10.1007/s002680020348.
9. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006;244:741-749. doi:10.1097/01.sla.0000224726.61448.1b.
10. Morínigo R, Moizé V, Musri M, Lacy AM, Navarro S, Marín JL, Delgado S, Casamitjana R, Vidal J. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006;91:1735-1740. doi:10.1210/jc.2005-0904.
11. Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-1716. doi:10.2337/dc06-1549.
12. Pacheco D, de Luis DA, Romero A, González Sagrado M, Conde R, Izaola O, Aller R, Delgado A. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 2007;194:221-224. doi:10.1016/j.amjsurg.2006.11.015.
13. Troy S, Soty M, Ribeiro L, Laval L, Migrenne S, Fioramonti X, Pillot B, Fauveau V, Aubert R, Viollet B, Foretz M, Leclerc J, Duchampt A, Zitoun C, Thorens B, Magnan C, Mithieux G, Andreelli F. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab 2008;8:177-179. doi:10.1016/j.cmet.2008.08.008.
14. Bose M, Oliván B, Teixeira J, Pi-Sunyer FX, Laferrère B. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg 2009;19:217-229. doi:10.1007/s11695-008-9696-3.
15. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-917. doi:10.1210/jc.76.4.912.
16. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-2940. doi:10.2337/diacare.26.10.2929.
17. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830. doi:10.1016/S0140-6736(02)07952-7.
18. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36) amide in type 1 diabetic patients. Diabetes Care 1996;19:580-586. doi:10.2337/diacare.19.6.580.
19. Ayala JE, Bracy DP, James FD, Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2008;PMID:19008308.
20. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981-E988.
21. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72. doi:10.1038/379069a0.
22. Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, Hellström PM. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-R916.
23. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100. doi:10.2337/diacare.28.5.10920.
24. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE, Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637. doi:10.2337/dc06-0703.
25. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987. doi:10.2337/dc07-0627.
26. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008;16:298-305. doi:10.1038/oby.2007.83.
27. Vidal J, Nicolau J, Romero F, Casamitjana R, Momblan D, Conget I, Morínigo R, Lacy AM. Long-term effects of Roux-en-y gastric bypass surgery on plasma GLP-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab 2008;PMID:19106269.
28. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lönroth H, Fändriks L, Ghatei MA, Bloom SR, Olbers T. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-785. doi:10.1097/SLA.0b013e3180caa3e3.
29. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1-11. doi:10.1097/01.sla.0000102989.54824.fc.
30. Koopmans HS, Sclafani A, Fichtner C, Aravich PF. The effects of ileal transposition on food intake and body weight loss in VMH-obese rats. Am J Clin Nutr 1982;35:284-293.
31. Strader A, Vahl T, Jandacek R, Woods S, D'Alessio D, Seeley R. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rat. Am J Physiol Endocrinol Metab 2005;288:E447-E453. doi:10.1152/ajpendo.00153.2004.
32. Stader A, Clausen TR, Goodin SZ, Wendt D. Ileal interposition improves glucose tolerance in low dose streptozocin-treated diabetic and euglycemic rats. Obes Surg 2009;19:96-104. doi:10.1007/s11695-008-9754-x.
33. Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Donini A. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg 2005;15:1258-1264. doi:10.1381/096089205774512573.
34. Wang TT, Hu SY, Gao HD, Zhang GY, Liu CZ, Feng JB, Frezza EE. Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg 2008;247:968-975. doi:10.1097/SLA.0b013e318172504d.
35. Kindel TL, Yang Q, Yoder SY, Tso P. Nutrient-driven lymphatic incretin secretion is different between diabetic, Goto-Kakizaki rats and Wistar rats. Am J Physiol Gastrointest Liver Physiol 2009;296:G168-G174. doi:10.1152/ajpgi.90506.2008.
36. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 1992;89:8641-8645. doi:10.1073/pnas.89.18.8641.
37. Shughrue PJ, Lane MV, Merchenthaler I. Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 1996;137:5159-5162. doi:10.1210/en.137.11.5159.
38. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998;141:179-186. doi:10.1016/S0303-7207(98)00096-3.
39. Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, Wardlaw SL. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90:359-365. doi:10.1210/jc.2004-1076.
40. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessler M. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006;14:1553-1561. doi:10.1038/oby.2006.179.
41. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479-2485. doi:10.1210/jc.2007-2851.
42. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007;3:597-601. doi:10.1016/j.soard.2007.08.004.
43. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E. The early effect of the Roux-en-Y Gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240:236-242. doi:10.1097/01.sla.0000133117.12646.48.
44. Swarbrick MM, Stanhope KL, Austrheim-Smith IT, van Loan MD, Ali MR, Wolfe BM, Havel PJ. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008;51:1901-1911. doi:10.1007/s00125-008-1118-5.
45. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiologic incretin in rat. J Clin Invest 1995;95:417-421. doi:10.1172/JCI117671.
46. Kolligs F, Fehmann HC, Goke R, Goke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-19. doi:10.2337/diabetes.44.1.16.
47. Parlevliet ET, Heijboer AC, Schröder-van der Elst JP, Havekes LM, Romijn JA, Pijl H, Corssmit EP. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2008;294:E142-E147. doi:10.1152/ajpendo.00576.2007.
48. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008;149:5670-5678. doi:10.1210/en.2008-0336.
49. Bikman BT, Zheng D, Pories WJ, Chapman W, Pender JR, Bowden RC, Reed MA, Cortright RN, Tapscott EB, Houmard JA, Tanner CJ, Lee J, Dohm GL. Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab 2008;93:4656-4663. doi:10.1210/jc.2008-1030.
50. Ballantyne GH, Farkas D, Laker S, Wasielewski A. Short-term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass. Obes Surg 2006;16:1189-1197. doi:10.1381/096089206778392158.
51. Lee WJ, Lee YC, Ser KH, Chen JC, Chen SC. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg 2008;18:1119-1125. doi:10.1007/s11695-008-9457-3.
52. Movassat J, Calderari S, Fernández E, Martín MA, Escrivá F, Plachot C, Gangnerau MN, Serradas P, Alvarez C, Portha B. Type 2 diabetes- a matter of failing β-cell neogenesis? Clues from the GK rat model. Diabetes Obes Metab 2007;9s2:187-195.
53. Goto Y, Kakizaki M, Masaski N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 1976;119:85-90.
54. Kimura K, Toyota T, Kakizaki M, Kudo M, Takebe K, Goto Y. Impaired insulin secretion in the spontaneous diabetes rats. Tohoku J Exp Med 1982;137:453-459. doi:10.1620/tjem.137.453.
55. Giroix MH, Vesco L, Portha B. Functional and metabolic perturbations in isolated pancreatic islets from the GK rat, a genetic model of noninsulin-dependent diabetes. Endocrinology 1993;132:815-822. doi:10.1210/en.132.2.815.
56. Homo-Delarche F, Calderari S, Irminger JC, Gangnerau MN, Coulaud J, Rickenbach K, Dolz M, Halban P, Portha B, Serradas P. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006;55:1625-1633. doi:10.2337/db05-1526.
57. Smith BR, Hinojosa MW, Reavis KM, Nguyen NT. Remission of diabetes after laparoscopic gastric bypass. Am Surg 2008;74:948-952.
58. Patriti A, Aisa MC, Annetti C, Sidoni A, Galli F, Ferri I, Gullà N, Donini A. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-Kakizaki rats through an enhanced Proglucagon gene expression and L-cell number. Surgery 2007;142:74-85. doi:10.1016/j.surg.2007.03.001.
59. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-2377. doi:10.2337/diacare.26.8.2370.